ST高升(000971) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥174,015,385.71, representing a 5.15% increase compared to ¥165,494,801.81 in the same period last year[8]. - The net profit attributable to shareholders was -¥5,739,939.17, an improvement of 77.94% from -¥26,021,160.27 year-on-year[8]. - Basic and diluted earnings per share improved to -¥0.0050 from -¥0.025, marking an 80.00% increase[8]. - The net profit attributable to shareholders was -5,739,939.17 CNY, a decrease in loss of 77.94% compared to the same period last year, primarily due to the failure of Shanghai Yingyue to meet performance commitments, requiring compensation of 32,969,408 shares[16]. - The company reported a net profit of RMB 21,928.09 million for the year 2019, with a commitment to achieve a minimum net profit of RMB 11,100.00 million for 2019[27]. - The company reported a net loss for the company in Q1 2021 was CNY 20,000,000, reflecting a significant increase in operating costs[55]. - The total comprehensive income for the first quarter was -5,845,141.79, compared to -26,189,503.47 in the previous period, indicating a significant recovery[57]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥55,873,187.01, a decline of 9.89% compared to -¥50,615,529.95 in the previous year[8]. - The net cash flow from investing activities was -2,101,811.68 CNY, a decrease of 89.68% compared to the same period last year, primarily due to a payment of 15 million CNY for the acquisition of Huachi shareholders[16]. - The net cash flow from financing activities was -4,805,395.58 CNY, compared to 0 CNY in the same period last year, mainly due to rental payments reported under the new leasing standards[17]. - The total cash inflow from operating activities was 180,587,633.71, compared to 158,094,431.87 in the previous period[64]. - The total cash outflow from operating activities was 236,460,820.72, compared to 208,709,961.82 in the previous period[64]. - The company experienced a net cash decrease of ¥62,766,495.42 during the quarter, highlighting challenges in cash management[65]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,131,760,275.76, down 1.35% from ¥2,160,900,455.00 at the end of the previous year[8]. - The total liabilities of the company reached 215,740 million yuan, representing a 176.85% increase compared to the previous period[38]. - The company's total liabilities as of March 31, 2021, were CNY 932,042,185.14, slightly down from CNY 937,669,410.22 at the end of 2020[49]. - The total amount of guarantees provided by the company is 2,157.4042 million yuan, with an outstanding principal and interest balance of 879.8496 million yuan as of the report date[24]. - The total amount of financing guarantees provided by the company to related parties was RMB 215,740.42 million, with an outstanding principal and interest balance of RMB 87,984.96 million as of the report date[28]. Shareholder Information - The total number of shareholders at the end of the reporting period was 22,934[12]. - The largest shareholder, Tianjin Baierke Medical Biotechnology Co., Ltd., holds 15.12% of the shares, amounting to 158,550,396 shares[12]. - The company did not engage in any repurchase transactions among the top shareholders during the reporting period[13]. - The company repurchased and canceled 6,717,799 shares as compensation for the performance shortfall of Shanghai Yingyue, with a total compensation of 32,969,408 shares required[20]. Compliance and Governance - The company has committed to not using its position to seek preferential treatment in transactions, ensuring fair market practices[25]. - The company has not provided guarantees to its original actual controller or other related parties, adhering to regulatory requirements[26]. - The company will strictly avoid any illegal occupation of funds or assets, ensuring compliance with financial regulations[25]. - The company has established a commitment to not transfer benefits to other units or individuals at unfair conditions[26]. - The company has pledged to participate in shareholder meetings and exercise rights equally without seeking improper benefits[25]. - The company has outlined that any violations of commitments will result in legal responsibilities, including compensation for losses incurred[25]. Legal Matters - The company is actively involved in legal proceedings regarding guarantees, with a total of 40 million yuan in guarantees related to a former controlling shareholder[36]. - The company is currently in litigation regarding a guarantee request, with a total of 20 million yuan involved, and the case is still under review[36]. - The company has ongoing legal proceedings regarding guarantees deemed invalid by the court, affecting liabilities of approximately 53,681.04 million yuan[37]. - The company is involved in multiple legal disputes with its actual controllers and related parties, with total claims exceeding 44,610 million yuan[37]. Research and Development - Development expenditures increased by 127.22% to 4,060,022.29 CNY, primarily due to R&D investments in projects like Aerospace Cloud Network[16]. - Research and development expenses for Q1 2021 were CNY 10,366,916.70, compared to CNY 10,957,268.83 in the previous period[55]. Market Strategy - The company has identified new strategies for market expansion and product development in its upcoming fiscal plans[38]. - The company aims to avoid or minimize related party transactions, adhering to principles of fairness and transparency in any unavoidable transactions[28].